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ess: Karinloedrup.carlseSummary We aimed to evaluate the efficacy and safety of fluticasone propionate
(FP) in children aged 12–47 months with recurrent/persistent asthma symptoms.
One hundred and sixty children (12–47 months) were randomised into this
multicentre, double-blind, placebo-controlled, parallel-group study, and treated
with either FP (100 mg bd) or placebo (2 puffs bd), both administered by metered-
dose-inhaler and BabyhalerTM for 12 weeks. The primary endpoint was percentage of
symptom-free 24 h periods.
Over weeks 1–12, FP-treated patients had significantly more percentage
symptom-free 24-h periods compared with placebo (odds ratio 0.53; 95% CI
0.29–0.95; P ¼ 0:035). Relative to baseline, where all patients were symptomatic
for at least 21/28 days of the run-in, the improvement equated to one additional
symptom-free 24 h period per week.
FP patients also had a significantly higher percentage of 24 h periods with no
wheeze or cough, the odds ratio for treatment difference corresponding to two
additional wheeze-free and one additional cough-free periods per week. FP was
well-tolerated, with similar reported adverse events in both groups. Urinary cortisol-
creatinine ratio was slightly decreased among FP patients after 12 weeks, but with
no clinical correlates.Elsevier Ltd. All rights reserved.
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young children.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Asthma is the most common chronic disease in
childhood.1,2 Typically, children younger than 4
years with persistent and/or recurrent episodes of
bronchial obstruction (BO) present with symptoms
of cough, wheeze and/or shortness of breath.
Although these symptoms may occur only in
association with viral infections, they may repre-
sent signs of early and persistent asthma, and when
chronic and/or persistent are likely to be indicative
of underlying airway inflammation.3 The duration
and the severity of these symptoms, the variability
in frequency, lack of prognostic factors and a
relative lack of objective measures to assess the
disease in this age group remains a challenge as
regards a clear diagnosis of asthma and its treat-
ment. Without clear markers in the youngest age
group of early asthma (in contrast to transient BO),
and granted that the recurrence and persistence of
BO is a sign of underlying airway inflammation,
anti-inflammatory agents, like inhaled corticoster-
oids (ICS), would be expected to be the most
effective treatment strategy in combination with
bronchodilators (when required).
International treatment guidelines already advo-
cate the use of ICS for the treatment of all
severities of persistent asthma in pre-school chil-
dren.4 However, current evidence for the efficacy
and safety of ICS in infants and toddlers is limited.
Most studies have investigated the effect of
beclomethasone dipropionate5–8 and budesonide
suspensions,9–14 and shown that ICS are effective
and well-tolerated for the management of symp-
toms and that early intervention may benefit lung
function development in older children.15 Recent
studies have also shown that fluticasone propionate
(FP) is beneficial in this age group.16–20 However,
pharmacokinetic data are lacking, and combined
efficacy and safety outcomes are limited.
It has been shown upon retrospective analysis
that children with frequent symptoms (defined as
symptoms X3 days per week and X75% days with
symptoms during a 4-week period) benefit the most
from treatment with an ICS compared with children
with less frequent symptoms.17 This study there-
fore aimed to prospectively confirm these findings
in a selected population of patients aged 1–4 years
with chronic persistent asthma-like symptoms.Secondarily we aimed to assess the safety and
tolerability of FP in these patients.Subjects and methods
Study design
This was a randomised, double-blind, placebo-
controlled, parallel-group study performed in 30
centres from nine countries. The treatment sche-
dule comprised a 4-week run-in, 12-week treat-
ment phase (visits at weeks 0, 4, 8 and 12) and a
follow-up 2 weeks after completion or withdrawal.
Inclusion criteria for the run-in period were age
12–47 months and at least two documented
episodes of wheeze and cough or physician-diag-
nosed asthma with one episode within the previous
4 weeks of Visit 1. Inclusion criteria for randomisa-
tion at the end of the run-in period were; symptom
score of X1 on at least 21/28 days of run-in,
symptoms on X3 days for each of the 4 weeks, a
total score for wheeze of X2 over the 28 days of
run-in, use of a short-acting b2-agonistX2 times in
the last week (prn basis), at least 80% compliance
with reporting symptoms and tolerated a face
mask. Symptoms were scored on a rating score of
0 for no symptoms, 1 for mild symptoms that were
not troublesome, 2 for moderate symptoms and 3
for severe, troublesome symptoms.
Patients were excluded from the run-in period if
they had received any corticosteroids within the
previous 4 weeks, had life-threatening asthma
(including hospital admission), were unable to
change from regularly scheduled b2-agonists to
prn use or had clinical or laboratory evidence of a
serious, uncontrolled systemic disease. Patients
were excluded if during the run-in they had
symptoms that were of concern to parents or
investigators or if they had received any corticos-
teroids, b-adrenergic antagonists (including
ophthalmics) or immunosuppressive agents. All
patients who experienced an exacerbation and
required treatment during the study were with-
drawn. This was to minimise any effect of oral
corticosteroids on cortisol measurements and the
study was too short to capture asthma exacerba-
tions as an outcome. The study protocol was
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Ethics Committees, conducted according to Good
Clinical Practice guidelines and the declaration of
Helsinki and signed informed consent was obtained
from parents before enrolment.
Treatment assignment
One hundred and sixty patients (109 boys) were
randomised; 79 patients to the FP group and 81
patients to the placebo group, using the GlaxoS-
mithKline computer program Patient Allocation for
Clinical Trials.
Treatment
Blinded study treatment was FP (2 50 mg bd) or
placebo (2 puffs bd) both delivered via MDI
propelled by HFA-134a and BabyhalerTM spacer
device with a facemask. Parents were instructed
in the correct use of study equipment at Visit 1.
Patients received salbutamol to use on an as
required’’ basis for relief of asthma symptoms.
Efficacy measures
The primary endpoint was the percentage of
symptom-free 24 h periods (cough, wheeze and
shortness of breath) over the entire treatment
period. Secondary efficacy measures included
percentage 24 h periods with no cough and percen-
tage 24 h periods with no wheeze, day- and night-
time scores for cough, wheeze and shortness of
breath and day- and night-time symptomatic use of
salbutamol. Parents reported their child’s day- and
night-time symptom scores either once or twice a
day (the evening call was mandatory) using the
Interactive Voice Recognition (IVR) system, Qto-
neTM (Quintiles, UK). No retrospective entries
beyond 24 h were permitted. Separate scores were
recorded for wheeze, cough and shortness of
breath. Parents also recorded the number of
occasions that salbutamol was given to relieve
asthma symptoms.
Humanistic measures
The functional status for each child was measured
by their parents by proxy using the Functional
Status II(R) (FSII-R) questionnaire.21 The investiga-
tor administered the questionnaire at Visits 2 and 5
in Australia, Canada, Germany, Italy, Latvia,
Lithuania, Norway and the UK. Parents in Australia,
Canada and the UK also recorded quality of life at
Visits 2 and 5 using The Paediatric AsthmaCaregiver’s Quality of Life Questionnaire (PACQLQ).
Whenever possible, the same parent completed
both questionnaires at both visits.
Safety measures
Adverse events
All adverse events or concurrent illness that
occurred during the study were documented and
oropharyngeal examinations were carried out at all
visits.
Urinary cortisol
Spot morning urine samples (before 10.00 h) were
collected at weeks 0, 4 and 12 at the same time of
day wherever possible. Urine was collected using
OntexTM pads22 for infants who were not toilet
trained. Cortisol and creatinine concentrations
were determined by Chiron ACS 180 chemilumines-
cence (direct) and Roche Hitachi alkaline/picric
acid (modified Jaffe), respectively.
Pharmacokinetic data
A single venous blood sample (4mL) was collected
at Week 12 from 94 patients whose parents
consented at four different time intervals relative
to the last morning dose: between 1 h and
immediately prior to morning dose; between
15min and 1.5 h post-morning dose; between 3
and 8 h post-morning-dose; and between 9 and 11 h
post-morning-dose. Plasma was stored at 20 1C
until assayed for FP by the Department of Interna-
tional Bioanalysis (Ware, UK) using solid phase
extraction in combination with liquid chromato-
graphy tandem mass spectrometry. The method has
been validated with a lower limit of quantification
of 10 pg/mL.
Statistical analyses
To ensure 80% power to detect a 15% difference in
the % of symptom-free 24 h periods between
treatment groups, 70 patients per group were
required, assuming a common standard deviation
of 29% seen in a previous study.19 The 5% level of
significance with 95% confidence intervals were
used. A 15% treatment difference was chosen since
this equates to an increase of one additional
symptom-free 24 h period per week (1/7 ¼ 14.2%).
The number of patients in each category: 0–25%,
425–50%, 450–75%, and 475% symptom-free
periods was compared between treatment groups
using a logistic proportional odds model for ordinal
response. Variables for baseline % symptom-free
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treatment were included in the model that was
used to estimate the treatment difference
(expressed as an odds ratio (OR) placebo/FP) and
corresponding 95% confidence interval. The per-
centage of cough-free and wheeze-free 24 h peri-
ods were analysed similarly. An increase in the
percentage of symptom-free 24 h periods per week
from 1 (14%) to 2 (28%) with treatment equates to
an OR of approximately 0.42. Similarly, an increase
from k to k+1, where k is the number of symptom-
free 24-h periods per week and 1pkp5, equates to
an OR in the range 0.42–0.56.
The Wilcoxon rank sum test was used to compare
day-time and night-time scores for cough, wheeze
and shortness of breath and day-time and night-time
use of salbutamol. Differences between treatment
groups for FSII-(R) and PACQLQ scores were evalu-
ated using ANCOVA with baseline score, age, sex and
treatment as covariates. The total number of with-
drawals and withdrawals due to lack of efficacy were
compared between groups using Fisher’s Exact test
(twice the one-sided test). Urinary cortisol adjusted
for creatinine was log-transformed then analysed
using ANCOVA with terms for baseline, age, sex and
treatment. FP plasma concentration-time data were
pooled and the concentrations smoothed using the
Lowess command in SigmaPlot Version 5.0 (SPSS Inc.,473 patients recruited
160 patients randomised
79 received fluticasone 
(100 µg bd) 
 5 patients withdrew 
2 AE due to lack
of efficacy
2 lost to follow up 
1 non-compliance 
74 completed



Figure 1 Patient accountabilChicago, USA). The area under the curve was
calculated for the smoothed FP plasma concentra-
tion-time profile using non-compartmental methods.
During the study, an audit at one of the sites raised
concerns regarding study conduct with respect to the
protocol and Good Clinical Practice. Therefore, the
efficacy analyses were repeated on a reduced
intention-to-treat (ITT) population (RITT) excluding
18 patients recruited from that site. This was to
support the findings of the overall ITT population.Results
Subjects
Of the 473 patients enrolled, 313 withdrew prior to
randomisation, mostly (45%) because they did not
meet the entry criteria for randomisation (Fig. 1).
Baseline characteristics were well-matched be-
tween the treatment groups (Table 1).
Primary efficacy measure
Over weeks 1–12, both groups improved from a
baseline of 0 symptom-free 24h periods although
patients in the FP group had significantly more313 patients withdrew 
17 Adverse event 
3 AE due to lack of efficacy
13 consent withdrawn
8 lost to follow up 
6 protocol violation 
214 did not fulfil entry criteria 
38 non-compliance 
14 other 
81 received placebo 
 11 patients withdrew 
2 adverse event 
4 AE due to lack
 of efficacy
1 lack of efficacy
2 lost to follow up 
2 non-compliance 
70 completed













ity throughout the study.
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Table 1 Patient baseline characteristics.
Characteristic FP (n ¼ 79) Placebo (n ¼ 81)
N (%) N (%)
Anthropometrics
Age (months) Mean (SD) 28.0 (10.6) 27.6 (11.4)
Age (months) o24 months 32 (41) 35 (43)
X24 months 47 (59) 46 (57)
Sex Male 57 (72) 52 (64)
Race Caucasian 75 (95) 78 (96)
Other 4 (5) 3 (4)
Height (cm) Mean (SD) 89.9 (9.4) 90.7 (10.1)
Weight (kg) Mean (SD) 13.8 (2.7) 14.0 (3.3)
Atopic history
Family history of atopy 71 (91) 71 (88)
Family history of asthma 45 (58) 44 (54)
Smoker in child’s primary environment 28 (36) 31 (38)
Symptoms median (range)
% Symptom-free 24 h periods 0 (0–24) 0 (0–24)
% Symptom-free 24 h periods of: 4 (0–81) 4 (0–80)
Cough 16 (0–96) 25 (0–93)
Wheeze 1.0 (0–3) 1.0 (0–2)
Day-time symptom scores for:
Cough 1.0 (0–2) 1.0 (0–2)
Wheeze 1.0 (0–2) 1.0 (0–2)
Shortness of breath 1.0 (0–2) 1.0 (0–2)
Night-time symptom scores for:
Cough 1.0 (0–.2) 1.0 (0–2)
Wheeze 1.0 (0–2) 1.0 (0–2)
Shortness of breath 1.0 (0–2) 0.0 (0–2)
Day-time Ventolin use 1.0 (0–4) 1.0 (0–9)
Night-time Ventolin use 1.0 (0–2) 0.0 (0–3)
Majority of patients had baseline score of 0 (i.e. no symptom free 24 h periods) as per inclusion criteria, therefore median is 0.
Symptom score definition; 0 ¼ no symptoms; 1 ¼ mild symptoms, not troublesome; 2 ¼ moderate symptoms; 3 ¼ severe,
troublesome symptoms.
Data missing for one patient in FP group.
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Efficacy and safety of FP in pre-school children 1397symptom-free 24h periods compared to placebo (Fig.
2; Table 2). Results for the RITT population were very
similar to those for the ITT (OR: 0.47; 95% CI 0.25–0.88;
P ¼ 0:020). More patients in the FP group had a higher
% symptom-free category as shown in Table 3.
There were no significant interactions between
treatment and baseline, sex, age and family history.
The treatment effect appeared larger in patients
with a family history of asthma (OR: 0.33) compared
to without (OR: 0.85), but the patients in the
placebo group with a family history tended to have
more symptoms than those with no history (Table 4).0
Baseline 1-4 5-8 9-12 1-12
Weeks
Figure 2 Effect of FP (100 mg bd) or placebo on %
symptom-free 24 h periods during weeks 1–4, 5–8, 9–12
and 1–12.Secondary efficacy measures
Compared to placebo, patients in the FP group
experienced significantly more % 24 h periods over
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Table 3 Number of patients with % symptom-free
days over weeks 1–12 in each % category (ITT
population).
FP Placebo
N (%) N (%)
Baseline: 40 and p25% 79 (100) 81 (100)
40 and p25% 30 (38) 42 (52)
425 and p50% 23 (29) 20 (25)
450 and p75% 18 (23) 13 (16)
475 and 100% 8 (10) 6 (7)
Odds ratio and 95% CI 0.53 (0.29, 0.95)
P ¼ 0:035
Table 2 Percentage of symptom-free 24 h period over weeks 1–12 (ITT population).
Percentage of symptom free 24 h periods Odds ratio placebo/FP Clinical benefit per week
24-h periods with no symptoms 0.53 (P ¼ 0:035) 1 additional day
24-h periods with no cough 0.54 (P ¼ 0:038) 1 additional day
24-h periods with no wheeze 0.28 (Po0:001) 2 additional days
Average comparison with placebo per week.
K.C.L. Carlsen et al.1398the 12-week treatment period with no wheeze (OR:
0.28; 95% CI 0.15–0.53; Po0:001) or cough (OR:
0.54; 95% CI 0.30–0.96; P ¼ 0:038), corresponding
to two additional wheeze-free and one additional
cough-free 24 h period per week. Day-time wheeze,
as well as both day- and night-time cough was
significantly reduced in the FP group compared to
placebo. A higher percentage of FP patients had a
median score of 0 for rescue use during the day
though this was not statistically significant. Night-
time use was similar in both treatment groups
(Figs. 3A and B) For all other symptom scores there
were no significant treatment differences (Figs. 3A
and B). Withdrawals from the placebo group
occurred at twice the rate of those from the FP
group (n ¼ 11 (14%) vs. n ¼ 5 (6%)), though this
difference was not statistically significant (FP-
placebo difference: 7%; 95% CI –18%, +3%;
P ¼ 0:205).Humanistic measures
No difference was detected in the mean change
from baseline between the treatment groups for
the FSII-(R) (P ¼ 0:570). The PACQLQ total score
tended to improve from baseline with a treatment
difference between the groups at week 12 of 0.47
(95% CI: 0.01–0.94) in favor of FP (P ¼ 0:055). Forthe emotional function domain of the PACQLQ, the
treatment difference was 0.53 in favor of FP (95%
CI: 0.05–1.00; P ¼ 0:032).
Safety measures
Adverse events
Similar numbers of patients in each treatment
group experienced at least one adverse event
during treatment: 55 patients (70%) and 59 patients
(73%) in the FP and placebo groups, respectively.
The most common events, drug-related events and
serious adverse events are summarised in Table 5.
Urinary cortisol
The ratio of week 12 to baseline values for the
cortisol creatinine ratio in the FP group was 0.8
compared to 1.1 in the placebo group for all
samples (FP/placebo ratio: 0.79; 95% CI 0.63– 0.99;
P ¼ 0:039). Figure 4 shows the relationship be-
tween baseline and 12week concentrations for
each sampled individual. There was no indication of
a trend for individual values to transition from high
to low, nor were there any adverse clinical events
related to decreases in cortisol levels.
Pharmacokinetic data
Ninety-four patients (n ¼ 49 FP; n ¼ 45 placebo)
provided blood samples of which 13 samples were
excluded from FP analysis (due to insufficient
sample volume, missing dosing or sampling infor-
mation or storage of sample for longer than 9
months). The FP AUC (0–12) was 157 pg h/mL
(Fig. 5). Therefore daily exposure following twice
daily dosing of 100 mg FP to this patient population
is estimated to average 314 pg h/mL.Discussion
The present study demonstrated that 100 mg FP bd
significantly reduced asthma symptoms in children
younger than 4 years. FP-treated patients had a
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FP
Placebo
Cough Wheeze Shortness of
breath
Rescue
medication
Cough Wheeze Shortness of
breath
Rescue
medication
FP
Placebo
(A)
(B)
Figure 3 (A) % patients with median day-time symptom
scores of 0 for weeks 1–12; (B) % patients with median
night-time symptom scores of 0 for weeks 1–12 in very
young children (12–47 months). (A and B) P values from
Wilcoxon rank sum test comparing distribution of scores
across treatment groups.
Table 4 Effect of fluticasone propionate (100 mg bd) on % symptom-free 24 h periods over weeks 1–12 in
patients with and without a family history of asthma (ITT population).
Number of patients with %
symptom-free days over
weeks 1–12 in each %
category
With a family history Without a family history
FP 100 mg bd Placebo FP 100 mg bd Placebo
N (%) N (%) N (%) N (%)
0% 6 (13) 14 (32) 7 (21) 7 (19)
40 and p25% 9 (20) 11 (25) 7 (21) 10 (27)
425 and p 50% 14 (31) 14 (32) 9 (27) 6 (16)
450 and p75% 13 (29) 4 (9) 5 (15) 9 (24)
475 and p100% 3 (7) 1 (2) 5 (15) 5 (14)
100% 0 0 0 0
Odds ratio (95% CI) 0.33 (0.15, 0.74) 0.85 (0.34, 2.07)
Table 5 Summary of the most common adverse
events, drug-related adverse events and serious
adverse events during treatment.
FP
N ¼ 79
Placebo
N ¼ 81
Any event n (%) 55 (70) 59 (73)
URTI 21 (27) 16 (20)
Fever 10 (13) 15 (19)
Ear, nose and throat
infectionsy
5 (6) 13 (16)
Asthma exacerbation 5 (6) 10 (12)
Drug-related adverse
event n (%)
2 (3) 3 (4)
Abnormal adrenal
hormone levelsz
2 (3) 2 (2)
Asthma exacerbation 0 1 (1)
Serious adverse event n (%) 3 (4) 6 (7)
Asthma exacerbation 2 (3) 3 (4)
Foreign bodies 0 1 (1)
Ear nose and throat
infections
0 1 (1)
Nausea and vomiting 0 1 (1)
Sleep disorder 1 (1) 0
Viral infection 0 1 (1)
Most common is defined as X10% of patients in any
treatment group.
yAs reported by investigators, in contrast to non-
specific upper respiratory tract infections.
zUrinary cortisol concentration increased from baseline
in four patients with no clinical correlates.
Efficacy and safety of FP in pre-school children 1399significantly higher % symptom-free 24 h periods and
% 24h periods without cough or wheeze compared
to placebo, corresponding to one additional symp-
tom-free, one additional cough-free and two addi-
tional wheeze-free 24 h periods per week. A slight
decrease in urinary cortisol/creatinine ratio after12 weeks treatment of FP was found, but without
clinical correlates. Pharmacokinetics demonstrated
an estimated average steady-state AUC of 157 pgh/
mL with FP 100mg bd exposure.
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K.C.L. Carlsen et al.1400The observed improvement of one symptom free
and two wheeze-free 24-h periods with active
treatment provides a clinically meaningful im-
provement among children with persistent asthma
symptoms. Our findings support the hypothesis
generated previously that treatment with FP was
more beneficial in pre-school children with moder-
ate to severe persistent symptoms than less
frequent symptoms as previously reported by
Roorda et al.17 This is one of the largest prospective
studies conducted to demonstrate an effect of an
ICS in such a specific patient population. The strict
inclusion/exclusion criteria in the present studyPlacebo FP 200
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Figure 4 Relationship between baseline and 12 week -
morning urinary free cortisol adjusted for creatinine
ratios following treatment with FP (100 mg bd) or placebo
for 12 weeks in children (12–47 months) with chronic
persistent asthma-like symptoms.
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Figure 5 FP concentrations in plaensured that only children with chronic persistent
asthma symptoms were randomised, minimising the
chance that their symptoms were viral-induced and
would improve spontaneously. Patients were also
required to show a level of wheeze and short-acting
b2-agonist use during run-in. Almost half of children
withdrawn prior to randomisation were because
they did not have chronic persistent asthma
according to the inclusion/exclusion criteria.
Treatment effect was evaluated by parents
collecting and reporting daily clinical symptom
scores and salbutamol usage using an IVR System.
This ensured that symptoms were reported at least
once daily, with no allowance for retrospective
entries, thereby increasing the authenticity of the
data. The results showed no significant difference
between the groups for night-time wheeze or day-
and night-time shortness of breath, which is in
accordance with other studies in young chil-
dren.15,18 Parents may observe wheeze and short-
ness of breath in their children less easily than the
more audible coughing, particularly at night if the
child does not wake up. Additionally, shortness of
breath was not frequently recorded at baseline,
indicating that the children may have limited any
shortness of breath by inactivity. The tendency
(although not statistically significant) towards more
frequent use of salbutamol in the placebo group,
with no differences in night-time salbutamol use,
renders rescue medication unlikely as an explana-
tion for the observed treatment response. The lack
of difference between the groups in night-time use
of salbutamol is probably due to parents giving
their children salbutamol prophylactically before
bedtime.
Although a significant treatment effect was seen
in both patients with and without a family historylast morning dose)
Actual Conc.
Averaged Conc
8 10 12
sma after 12 weeks (N ¼ 24).
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This may suggest that family history is a predictor
of treatment response to an ICS, supported by the
identification of family history of asthma, positive
skin prick test to allergens and high serum IgE
concentration as risk factors for asthma symptoms
to persist in young children.23 A recent post-hoc
analysis of two dose ranging studies showed that
children with a family history of asthma and/or
frequent symptoms showed the greatest response
to FP treatment.17 Our result should, however, be
interpreted with caution as the analysis included a
small number of patients.
In this study, neither humanistic health outcomes
questionnaire showed statistically significant dif-
ferences between the treatment groups for the
overall score. Statistical significance may not have
been achieved as the PACQLQ was only comple-
ted in English speaking countries where recruit-
ment was less, which reduced the sample size
considerably. In addition, the baseline values
recorded in both groups were also surprisingly high
considering the symptom requirement during run-
in, which left little room to show an improvement.
These questionnaires are yet to be validated in this
age group.
There is little information regarding the safety of
ICS in infants and toddlers. This study demon-
strated a 20% reduction in urinary cortisol cor-
rected for creatinine after treatment with FP. The
clinical relevance is not clear as it is unlikely that
clinical sequelae would be observed in this short
treatment period. Cortisols were measured, how-
ever, as part of due diligence and patient safety
even though the treatment period was short. In the
present study no adverse events were attributable
to cortisol suppression, and there was a similar
incidence of adverse events reported in both
groups. Spot urinary free cortisol concentration is
not as robust as 12 h urinary cortisols, but was
chosen for practical reasons in this moderate to
severe asthma population. Although there was
evidence of reduced values, this type of measure-
ment probably overestimates the true effect on
24 h cortisol levels. This is supported by the
fluticasone plasma concentration data, which
showed exposures well below both the 1000 pg h/
mL plasma 24 h AUC threshold for detectable
cortisol suppression and the 3200 pg h/mL 24 h
AUC associated with 50% cortisol suppression.24
Data collected from a long-term (12 months)
parallel study in milder asthma patients in this
age group showed a similar response to our short-
term study. Treatment with FP 200 mg/day showed a
reduction in 12 h urinary cortisols,16 with no effect
on growth or other clinically important side-effects. It is, however, important to monitor this
patient population carefully and to titrate down to
the lowest dose, since serious adverse reaction
with higher doses of FP (500–2000 mg) have been
reported.25,26
Daily exposure following twice daily dosing of FP
(100 mg) in this patient population is similar to
results seen in older children with a powder inhaler.
This provides evidence for a similar level of lung
delivery of FP in this population compared with
adults and older children, and indicates that the
MDI and BabyhalerTM is an efficient delivery system
in very young children with persistent asthma-like
symptoms.
In conclusion FP (200 mg/day) reduced symptoms
in very young children with persistent asthma, with
no clinically detectable adverse events attributable
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